Researchers investigated subgroups of patients with chronic rhinosinusitis with polyposis (CRSwNP), wanting more data on their responses to dupilumab and hoping to stratify their level of benefit.
Dupilumab efficacy in chronic rhinosinusitis with polyposis (CRSwNP) was further confirmed in a new study out of Germany, with findings showing the monoclonal antibody to have great benefit regarding endoscopic findings, objective smell tests, and subjective findings. The 75 patients in the study, subdivided by disease type—aspirin-exacerbated respiratory disease (AERD), increased histologic eosinophilia, or elevated blood eosinophil or immunoglobulin E (IgE) levels—showed consistent benefit independent of disease characteristics.
Findings were recently published in Medicine, with the study authors noting, “There is little information on several subgroups of dupilumab treatment in CRSwNP. As treatment with dupilumab is associated with considerable costs, accurate knowledge of the expected efficacy is crucial.”
Chronic rhinosinusitis diagnosis was confirmed using American Academy of Otolaryngology Head and Neck Surgery criteria, and their nasal polyps were confirmed via European Forum for Research and Education in Allergy and Airway Diseases criteria. Their screening comprised the following: IgE and eosinophil count, nasal endoscopy, brief identification of smell test (BSIT), short version of the University of Pennsylvania Smell Test, histology, and completion of the Sinus Nasal Outcome Test (SNOT-22). Visual Analogue Scale (VAS) and SNOT-22 scores indicated disease burden. Dupilumab was self-administered using six 300-mg ready-to-use pens, with 1 pen administered every 2 weeks, which was switched to every 4 weeks once adequate disease control was achieved, gauged by at least a one-third score improvement on the VAS or SNOT-22. Follow-up visits took place every 3 months.
Among the 75 original patients (male patients, 65.3%), 55 responded to a follow-up inquiry in March 2021. Their most common disease subtype was histologic eosinophilia, at 85.7%, with 65.3% reporting AERD. The mean (SD) serum eosinophilic level was 0.46 (0.32) x 103/mcL.
When treatment with dupilumab began, the following mean (SD) measures were seen:
Three of these measures had dropped by the first 2-week follow-up visit, while BSIT rose:
Over the remaining follow-up visits, scores remained consistent, with the endoscopy measures coming in at 1.3 (1.8) and 1.1 (1.9); VAS, 2.7 (1.8) and 2.0 (1.0); SNOT-22, 20.7 (13.5) and 16.6 (10.9); and BSIT, 7.6 (3.4) and 7.4 (3.7). The mean overall eosinophil count was 70.7 (21.9)/HPF.
The study authors noted that they found “very little significant differences in treatment success between different patient groups.” In addition, they only saw a significant difference in SNOT-22 when considering histologic eosinophilia, with the baseline measure being 81.8 (65.4) and the first follow-up visit measure coming in at 24.3 (14.5). Similar results were not seen at the remaining follow-ups.
Forty-one patients were transitioned to dupilumab every 4 weeks following successful therapy initiation, and of this group, 36.5% requested a return to administration every 2 weeks after symptom worsening. However, patients on concomitant medications dropped in all categories following dupilumab initiation (all P = .001):
The most common adverse effects with dupilumab were weight gain (21.8%), myalgias (20.0%), and migraines (14.5%).
The authors’ findings are strong in that they echo previous data on dupilumab efficacy and perhaps even show greater benefit from the treatment, which they note “may be due to the fact that a considerable proportion of the patients suffered from substantial type-II inflammation, as is vividly displayed by the extensive eosinophil tissue counts.”
One major limitation on their results is that the patients treated just with dupilumab all had a history of functional endoscopic sinus surgery (FESS) “without longer-lasting disease control, potentially causing a considerable bias.” Therefore, further studies should investigate why patients who have CRSwNP and undergo FESS tend to have disease relapse requiring additional treatment and surgeries despite “adequate postoperative care.”
Reference
Bertlich M, Freytag S, Dombrowski T, et al. Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study. Medicine (Baltimore). Published online November 11, 2022. doi:10.1097/MD.0000000000031031
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More